Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First
Executive Summary
Novartis is in the process of "exiting" the "small number" of scientists involved in the fraud, CEO Narasimhan says.
You may also be interested in...
Data Integrity ‘More Than Just A GMP Issue’ As Attention To Clinical, Nonclinical Lapses Grows
Sponsors should notify US FDA quickly when they detect data quality issues in preclinical and clinical research, particularly for applications under review, experts say in a rebuke to Novartis’ delayed notification about Zolgensma data manipulation.
Clinical Data Fraud Involving CROs Attracting US Justice Department Attention
Submission of manipulated clinical data to support product approval is a ‘major concern’ for the DoJ, consumer protection branch director Gusav Eyler says, adding that some of the problems relate to outsourcing of trials. Also, DoJ and HHS OIG are using data analytics to identify outliers in prescribing and reimbursement claims.
Novartis Says SMA Baby Death Not Due To Zolgensma
The Swiss major has new data on its SMA gene therapy which has been found not to be the cause of the death of a six-month-old patient earlier this year.